Buy Selank Nasal Spray: Nobody Compounded That Bottle

People who buy Selank nasal spray are usually buying the format rather than the compound, because intranasal is how this peptide reached consumers in the first place and the search results reflect that. A spray bottle looks finished. It has a pump, a volume, a shelf life printed somewhere, and it asks nothing of the buyer. That impression of a finished product is the thing worth examining, because a bottle can look exactly like a pharmacy item and have none of the apparatus behind it.

Selank is a synthetic heptapeptide, seven residues in the order Thr-Lys-Pro-Arg-Pro-Gly-Pro, built as an analogue of the immune peptide tuftsin with a Pro-Gly-Pro tail added to slow enzymatic breakdown. PubChem lists it as CID 11765600, formula C33H57N11O9, molecular weight 751.9. It is registered as an anxiolytic in Russia. That registration is a fact about Russia and it does not travel: there is no FDA approval for Selank in the United States for any indication, in any format, and a spray bottle does not change that.

So the practical question is not spray or vial in the abstract. It is what each listing tells you about the material inside, and which of those claims you can check. That is the whole of this page, and the answer runs against the format most people arrive wanting.

We earn a commission if you buy through our link, which our affiliate disclosure explains. The listing we link is a 10 mg lyophilised vial. It is not a nasal spray, and we are not going to pretend it is one or tell you how to turn it into one.

A lyophilised vial is freeze-dried powder under a stopper, sealed, dry and dated by batch. Dry powder is the stable form of a peptide, which is why almost every research supplier ships it that way. What you are buying is a quantity of material and a document that describes that batch, and nothing about the vial anticipates any particular route of administration.

A pre-filled spray is a solution already made up: peptide, water, usually a preservative, in a pump bottle at a stated volume. Somebody has already decided the concentration, the preservative and the fill, and the entire value of the format is that those decisions were made for you. The question that follows is unavoidable. Who made them, to what standard, and what proves it.

That is where the two formats separate, and it is not really a chemistry argument. A vial listing that publishes a batch certificate is making a checkable claim about a defined quantity of powder. A spray listing that states neither the peptide content of the bottle nor a lot number is making no checkable claim at all, and the convenience you are paying for is the part nobody documented.

There are two lawful ways a nasal spray normally reaches a patient in the United States, and Selank is on neither of them. The first is an FDA approved product, manufactured under current good manufacturing practice, with a manufacturer that owns the formulation, a labelled expiry supported by stability data, a lot number that can be traced, and a recall mechanism if a batch goes wrong. The second is a compounded preparation, made by a licensed pharmacy against a prescription, with a pharmacist responsible for it, a beyond-use date rather than an expiry, and a state board that can be complained to.

Selank cannot take the second route because a compounding pharmacy has nothing to work from. The 503A bulks list is the register of substances a pharmacy may lawfully compound with, and the FDA page carrying it is current as of 05/14/2026 with no mention of Selank on it. On FDA's compounding safety page, current as of 04/22/2026, Selank acetate (TP-7) appears in the table of bulk drug substances nominated but withdrawn, alongside BPC-157, MOTs-C and Semax. It is not in the category 2 table, which names substances such as cesium chloride and kisspeptin-10. Nominated, then withdrawn, and on no current list is the accurate description, and it is the reason no pharmacy in the country can fill this.

What that means for a bottle in your hand is specific rather than rhetorical. Nobody licensed chose the concentration. Nobody licensed chose the preservative, or decided whether the solution needed one. No beyond-use date was assigned by a pharmacist who knew what was in it. There is no recall route, no dispensing record and no board with jurisdiction. Our page on the formats a pharmacy would reject makes the same point about a different peptide sitting in that same withdrawn table, and the pattern is worth recognising: the more finished a grey-market product looks, the more decisions were made for you by somebody you cannot name.

FDA's stated concern about compounded Selank is immunogenicity for certain routes of administration, arising from the potential for aggregation and peptide-related impurities, and the agency records that it lacks important information about safety issues raised by selank acetate given to humans. The phrase carrying the weight there is certain routes of administration, because what a document needs to cover depends on where the material is going.

For anything injected, endotoxin testing is the line that matters, because bacterial endotoxin survives sterilisation that kills the bacteria themselves and a purity assay will not see it. A sterility result matters for the same reason. For a liquid sitting in a multi-dose pump bottle that gets used repeatedly over weeks, the questions widen rather than narrow: microbial growth over the life of the bottle, whether a preservative is present, whether the solution is stable at room temperature, and what happens at the tip of an applicator that touches a mucous membrane and goes back on a shelf. A dry powder in a sealed vial does not raise those questions until somebody puts it into water.

This is where the certificates on the product we link become genuinely useful, and where the answer changed during 2026. The February 2026 document for lot 29-01260229 reports 99.32% purity by HPLC-UV and identity by mass spectrometry, with the measured monoisotopic mass at 751.47 Da against an expected 751.43, and a measured quantity of 12.29 mg in a 10 mg vial. It contains no endotoxin test, no sterility test and no heavy metals screen. The document for the current batch, 29-05260628, is a different animal: 99.371% purity, 11.86 mg net content, a bacterial endotoxin analysis by kinetic LAL to USP Chapter 85 reporting under 0.20 EU/mL against a 0.5 EU/mL acceptance limit, a rapid sterility screen returning no growth, and ICP-MS heavy metals with lead, arsenic, cadmium and mercury all below limit.

Read that second document rather than take our summary of it, because it is candid about its own limits in a way that is unusual and useful. The sterility page states in its own methodology note that this is a rapid screening method providing a preliminary sterility assessment suitable for quality control purposes, and that full compendial sterility testing may be required for regulatory compliance. The endotoxin report also describes its assay as kinetic chromogenic in the heading and kinetic turbidimetric in the methodology table, which is the kind of discrepancy you only find by opening the file. Neither point makes the testing worthless. Both are what reading a certificate properly actually looks like, and both are more information than any pre-filled spray listing we have seen offers about anything.

If you are set on a bottle, the listing has to answer five things before the price is even relevant, and most of what is for sale answers none of them.

How much peptide is in the bottle, in milligrams, not in sprays or in percentage terms. What the total fill volume is, so the two numbers give a concentration. What the lot number is, so the certificate can be matched to the bottle rather than to the product line. What testing that lot had, specifically whether anything beyond purity and identity was run. And how it should be stored and for how long once opened, since a solution and a sealed powder do not behave the same way on a shelf.

A listing missing the milligram content is also impossible to price. A per bottle figure with no stated quantity cannot be converted into a cost per milligram, so it cannot be ranked against the $2.38 per milligram we work through on our Selank price page. The bottle that looks cheaper may hold a fraction of the material, and there is no way to tell from the outside.

One more thing belongs on the list and rarely appears anywhere. Ask what the seller says the product is for. A listing that describes a research chemical and states it is not for human consumption is at least consistent with what it is allowed to sell. A listing that describes dosing, benefits or a schedule has stepped over a line that FDA does police, and a seller comfortable with that claim is telling you something about the rest of its claims too.

The vial is the more documented purchase and the less finished one. The spray is the more finished purchase and the less documented one. That trade is the whole decision, and it is worth stating plainly that neither option is a medicine, neither has been approved for any use in the United States, and neither passed through anybody with a professional licence on its way to you.

We do not publish preparation steps, concentrations or schedules for Selank in any format, and that is a settled position rather than an omission. There is no approved labelling to base them on, the compound is sold for laboratory use, and a page that supplies the missing instructions is quietly manufacturing the confidence that the absence of a prescription route ought to prevent. What we will do is tell you what the paperwork says and where it stops, which is the subject of our page on the regulatory position in full, and our safety guide for the general version of the argument.